Vibrio cholerae O1 Inaba (V. cholerae O1 Inaba)

Vibrio cholerae O1 Inaba is a specific serotype of the Gram-negative bacterium Vibrio cholerae, which is the primary causative agent of the severe diarrheal disease known as cholera [1]. It is distinguished from other serotypes, such as Ogawa, by the specific structure of its O1 lipopolysaccharide (LPS) antigen, which lacks a 2-O-methyl group on the terminal perosamine unit [2]. The pathogenicity of this organism is primarily driven by the production of cholera toxin, a potent enterotoxin that disrupts ion transport in the intestinal epithelium, leading to rapid and life-threatening fluid loss [3]. While not a single molecular receptor, it serves as the target for various therapeutic interventions, including antibiotics like doxycycline and azithromycin that inhibit bacterial growth, and oral cholera vaccines that elicit protective mucosal immunity [4]. Monitoring the Inaba serotype is essential for global health surveillance, as the bacterium can undergo serotype switching, impacting the effectiveness of long-term immunity and vaccine strategies [5]. This serotype is a critical component of the World Health Organization's strategy to reduce cholera deaths globally [1]. Clinical management focuses on aggressive rehydration and the use of antimicrobial agents to shorten the duration of symptoms [3]. The Inaba serotype often emerges in populations with high pre-existing immunity to the Ogawa serotype, illustrating the pathogen's evolutionary adaptability [5].

Other names

Inaba serotypeVibrio cholerae O1 serotype InabaVibrio cholerae serogroup O1 serotype Inaba

Antibiotics target the bacterial ribosome (30S or 50S subunits) to inhibit protein synthesis or DNA gyrase to inhibit replication, while vaccines provide the O1 antigen to stimulate the production of protective mucosal IgA antibodies that prevent bacterial colonization.